We are sharply focused on making breakthroughs in therapeutic areas of the future.
Building on our strong legacy of innovative medicines, our focus is developing new medicines within the areas of neuroscience, oncology, infection, cardiovascular, and respiratory/inflammation.
Globally, we are investing $17 million/day in R&D, including 20 drug development projects for personalized health initiatives.
For an overview of our current pipeline of new medicines and vaccines, visit:
